Agile Therapeutics, Inc. Announces the Resignation of Elizabeth Garner as Senior Vice President and Chief Medical Officer, with Effect from July 15, 2019
July 01, 2019 at 06:06 am EDT
Share
On June 28, 2019, Agile Therapeutics, Inc. announced that Dr. Elizabeth Garner, M.D., M.P.H., the Company's Senior Vice President and Chief Medical Officer, has accepted an offer to pursue another career opportunity and will be departing the Company effective July 15, 2019. Dr. Garner is working with the Company on the transition plan and has committed to supporting the Company's efforts to seek approval of Twirla. Dr. Garner will serve as a consultant to the Company on an as needed basis for a monthly retainer through December 31, 2019 (which includes the Company's PDUFA (the Prescription Drug User Fee Act) goal date) in order to assist with, among other things, the Company's scheduled Advisory Committee Meeting on October 30, 2019.
Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Its initial product, Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on its proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Its potential product pipeline consists of two types of product candidates: a progestin-only (P-only) contraceptive patch and potential Twirla line extensions.
Agile Therapeutics, Inc. Announces the Resignation of Elizabeth Garner as Senior Vice President and Chief Medical Officer, with Effect from July 15, 2019